PharmaKure, a clinical stage pharmaceutical company is targeting neurodegenerative diseases including Alzheimer’s and Parkinson’s Diseases and other rare diseases.
The company’s propriety technology allows the diagnosis and monitoring of drug treatment for patients using blood-based biomarkers.
Our lead drug candidates target the neuro toxic proteins that cause these diseases. The biomarkers monitor effectiveness by measuring changes in levels of these biomarkers in the patient’s blood.
This combined approach is unique and is helping us develop current and future therapies with the aim of bringing cost effective treatments rapidly to the market.